Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor at once, a design class the literature has come to call a "twincretin." It was developed by Eli Lilly under the code LY3298176 and later approved by the FDA as the active ingredient in two prescription medicines. Researchers study it as a case example of dual incretin-receptor pharmacology and as the structural backbone against which newer multi-receptor candidates, like retatrutide, are compared.
| Attribute | Detail |
|---|---|
| Class | Dual GIP and GLP-1 receptor agonist ("twincretin") |
| Backbone length | 39-amino-acid linear peptide |
| Molecular weight | 4810.52 Da (Coskun et al., 2018) |
| Key modifications | Aib (alpha-aminoisobutyric acid) at positions 2 and 13; amidated C-terminus; C20 fatty diacid conjugated via a linker at the lysine residue at position 20 |
| Originator | Eli Lilly and Company (research code LY3298176) |
| Approved medicines built on it | Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both FDA-approved prescription drugs |
| What the literature examines | Receptor binding and signaling assays, rodent metabolic models, and phase 1 to phase 3 human trials of the approved medicines |
| Form supplied here | Lyophilized powder, for laboratory research only |
How Was Tirzepatide Designed?
Tirzepatide's peptide backbone was engineered from the GIP receptor-agonist sequence and then modified to add GLP-1 receptor activity, rather than being built from the GLP-1 sequence outward. According to the discovery paper published by Lilly scientists, LY3298176 "is a 39 amino acid linear peptide conjugated to a C20 fatty diacid moiety via a linker connected to the lysine residue at position 20," and it "contains two non-coded amino acid residues at positions 2 and 13 (Aib, alpha-amino isobutyric acid)," with an amidated C-terminus (Coskun et al., 2018). The Aib substitutions are a common strategy in peptide engineering to reduce cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly degrades native incretin hormones. The C20 fatty diacid is a separate modification: it lets the peptide bind circulating albumin, which the same paper notes "enables albumin binding" and is the basis for the molecule's extended half-life relative to native GIP or GLP-1 (Coskun et al., 2018).
What Does "Dual GIP and GLP-1 Receptor Agonism" Mean?
GIP and GLP-1 are both incretin hormones released from the gut that act on distinct class B G-protein-coupled receptors expressed on pancreatic beta cells, among other tissues (Coskun et al., 2018). A conventional GLP-1 receptor agonist engages only the GLP-1 receptor. Tirzepatide was designed to engage both receptors from a single molecule, and its binding affinity has been characterized directly: in vitro receptor binding assays reported a GIP receptor Ki of 0.135 nM and a GLP-1 receptor Ki of 4.23 nM, described by the study authors as "comparable to native GIP for the GIPR and approximately 5-fold weaker than native GLP-1 for the GLP-1R" (Coskun et al., 2018). That intentional imbalance, full potency at GIPR paired with partial potency at GLP-1R, is the specific pharmacological signature that separates tirzepatide from single-receptor GLP-1 agonists in receptor-level assays. A follow-up mechanistic study in obese mice examined this further using wild-type and Glp-1r-null animals to isolate the GIP-receptor-specific contribution, and reported that GIP-receptor agonism produced insulin-sensitizing effects on glucose disposal in white adipose tissue that were independent of GLP-1-receptor-driven weight loss, associated with changes in circulating branched-chain amino acids (Samms et al., 2021).
Mounjaro and Zepbound: The Approved Medicines Context
Tirzepatide is the active ingredient in Mounjaro, an FDA-approved prescription medicine for type 2 diabetes, and in Zepbound, an FDA-approved prescription medicine for chronic weight management (U.S. Food and Drug Administration, Mounjaro prescribing information; FDA, Zepbound approval announcement). The FDA-approved prescribing information for Mounjaro describes the active ingredient in structural terms: "Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life" (Mounjaro prescribing information). The research-grade tirzepatide sold on this site is not Mounjaro, not Zepbound, and not any other approved medicine. It is not for human or animal use, and it is supplied strictly for laboratory research. The Mounjaro label also carries a boxed nonclinical toxicology finding worth noting for researchers: in rat carcinogenicity studies, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, and the label states that human relevance of this rodent finding has not been determined (Mounjaro prescribing information). That is a nonclinical, rodent-study finding disclosed in the approved drug's label, not a claim about any research use.
What Have the SURPASS and SURMOUNT Trials Examined?
Lilly's tirzepatide clinical program is organized into two trial families named SURPASS (type 2 diabetes) and SURMOUNT (obesity/weight management), both run to support the respective FDA approvals. SURPASS-1 was a 40-week, phase 3, double-blind, randomized, placebo-controlled trial that enrolled adults with type 2 diabetes who were treatment-naive to injectable therapy; it randomized participants to weekly tirzepatide at 5, 10, or 15 mg or to placebo and measured change in glycated hemoglobin (HbA1c) from baseline at 40 weeks as its primary endpoint (Rosenstock et al., 2021). SURMOUNT-1 was a 72-week, phase 3, double-blind, randomized, controlled trial in adults with obesity, or with overweight plus at least one weight-related complication other than diabetes; it used percentage change in body weight and a threshold weight-reduction response as coprimary endpoints across the same three weekly dose arms compared with placebo (Jastreboff et al., 2022). Both trials are published, peer-reviewed sources of efficacy and safety data for the approved medicines; neither trial, nor this article, describes outcomes for the unapproved, research-grade material sold here, which has not been studied clinically.
What Preclinical Models Have Examined Tirzepatide?
Before the human trials, Lilly's discovery team characterized LY3298176 in vitro using signaling and functional assays in cell lines expressing recombinant or endogenous GIP and GLP-1 receptors, and in vivo in mice measuring body weight, food intake, insulin secretion, and glycemic profiles (Coskun et al., 2018). A separate mechanistic study used obese wild-type mice alongside Glp-1r-null mice, a genetic model lacking the GLP-1 receptor, to determine what the GIP-receptor component of the dual-agonist activity contributed on its own. That study reported that tirzepatide improved insulin sensitivity in obese mice through both weight-dependent and weight-independent mechanisms, and that the weight-independent component tracked with GIP-receptor-driven glucose disposal in white adipose tissue and with changes in circulating branched-chain amino acid and ketoacid levels (Samms et al., 2021). These rodent and cell-based models are the type of experimental systems referenced when the literature discusses tirzepatide's mechanism, distinct from the human clinical trial data cited above.
How Does Tirzepatide Differ From Semaglutide and Retatrutide?
Semaglutide is a selective GLP-1 receptor agonist: it engages one incretin receptor. Tirzepatide adds GIP receptor engagement to that GLP-1 activity, making it a dual agonist. Retatrutide extends the same design logic further by adding glucagon receptor agonism on top of GIP and GLP-1, making it a triple agonist and the subject of separate, earlier-stage research. A side-by-side breakdown of receptor targets, backbone design, and trial status across all three is covered in more depth in our semaglutide vs. tirzepatide vs. retatrutide comparison and in the blog post on how the three incretin peptides differ in the lab. For a deeper monograph on tirzepatide specifically, including citations organized by topic, see the tirzepatide research library page.
| Compound | Receptor target(s) | Agonist class |
|---|---|---|
| Semaglutide | GLP-1 receptor | Single (selective GLP-1RA) |
| Tirzepatide | GIP receptor + GLP-1 receptor | Dual ("twincretin") |
| Retatrutide | GIP receptor + GLP-1 receptor + glucagon receptor | Triple agonist |
Handling Notes for the Research Bench
Research-grade tirzepatide is supplied as a lyophilized (freeze-dried) powder to preserve peptide stability during storage and transit. Reconstitution, the process of dissolving the lyophilized powder in an appropriate diluent for bench use, is a matter of solvent selection and concentration math, not a dosing instruction. The step-by-step math for calculating concentration from a given diluent volume, along with general guidance on storage temperature, light exposure, and freeze-thaw handling for a reconstituted vial, is covered in our guide to reconstituting lyophilized peptides. Our lyophilized tirzepatide lot page, listing current certificate-of-analysis data for the material sold here, is available on the tirzepatide product page.
Frequently asked questions
Is tirzepatide the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are FDA-approved prescription medicines that contain tirzepatide as their active ingredient, manufactured and labeled under FDA oversight for specific approved uses. The research-grade tirzepatide sold here is a different product: it is not an approved drug, is not for human or animal use, and is intended strictly for laboratory research.
What is a "twincretin"?
Twincretin is a term used in the pharmacology literature to describe a molecule engineered to agonize two incretin receptors, GIP and GLP-1, at once, rather than only one. Tirzepatide is the reference example of this design class studied in the published literature.
What makes tirzepatide structurally different from native GIP or GLP-1?
According to its discovery publication, tirzepatide carries two Aib (alpha-aminoisobutyric acid) substitutions at positions 2 and 13, an amidated C-terminus, and a C20 fatty diacid moiety attached through a linker at the lysine residue at position 20, none of which are present in the native hormones (Coskun et al., 2018). These modifications are associated with resistance to enzymatic degradation and with albumin binding.
What do the SURPASS and SURMOUNT trials tell researchers?
They are the published, peer-reviewed phase 3 clinical trials that supported FDA approval of the tirzepatide-containing medicines Mounjaro (SURPASS program, type 2 diabetes) and Zepbound (SURMOUNT program, weight management). They document endpoints, trial design, and reported findings for those approved drugs in defined patient populations; they are not data on the unapproved research material sold here.
How is tirzepatide different from retatrutide?
Tirzepatide is a dual agonist engaging the GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. The two compounds are compared side by side in our three-way comparison page.
How should lyophilized tirzepatide be stored before use?
General handling principles for lyophilized peptides, including temperature, light exposure, and reconstituted-versus-lyophilized stability windows, are covered in our reconstitution guide. This article does not provide dosing or administration instructions.
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/
- Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021;131(12):e146353. https://pubmed.ncbi.nlm.nih.gov/34003802/
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398(10295):143-155. https://pubmed.ncbi.nlm.nih.gov/34186022/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
